DK2016194T3 - Fremgangsmåder og sammensætninger til ekspression af viralt negativ-sense-rna i hundeceller - Google Patents

Fremgangsmåder og sammensætninger til ekspression af viralt negativ-sense-rna i hundeceller Download PDF

Info

Publication number
DK2016194T3
DK2016194T3 DK07760860.2T DK07760860T DK2016194T3 DK 2016194 T3 DK2016194 T3 DK 2016194T3 DK 07760860 T DK07760860 T DK 07760860T DK 2016194 T3 DK2016194 T3 DK 2016194T3
Authority
DK
Denmark
Prior art keywords
virus
influenza
cells
canine
rna
Prior art date
Application number
DK07760860.2T
Other languages
English (en)
Inventor
Gregory Duke
George Kemble
Zhaoti Wang
James Young
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2006/023867 external-priority patent/WO2007002008A2/en
Priority claimed from US11/501,067 external-priority patent/US7790434B2/en
Application filed by Medimmune Llc filed Critical Medimmune Llc
Application granted granted Critical
Publication of DK2016194T3 publication Critical patent/DK2016194T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
    • C12N2830/205—Vector systems having a special element relevant for transcription transcription of more than one cistron bidirectional
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (18)

1. Isoleret nukleinsyre, som omfatter en hunde-RNA-polymerase I-promotor, hvor nukleinsyren omfatter (a) et polynukleotid med nukleotidsekvensen ifølge SEQ ID NO: 26, (b) et funktionelt aktivt fragment af polynukleotidet som defineret i (a), hvilket fragment omfatter mindst 250 eller mindst 350 eller mindst 450 sammenhængende nukleotider fra sekvensen ifølge SEQ ID NO: 26, eller (c) et polynukleotid, som udviser mindst 99% identitet med polynukleotidet som defineret i (a).
2. Isoleret nukleinsyresekvens ifølge krav 1, som er operativt forbundet til cDNA, der koder for et viralt, genomisk negativ-streng-RNA eller det tilsvarende cRNA.
3. Isoleret nukleinsyre ifølge krav 2, hvor det virale, genomiske negativ-streng-RNA er et genomisk influenza-RNA.
4. Isoleret nukleinsyre ifølge krav 2 eller 3, hvor nukleinsyren endvidere omfatter en transskriptionstermineringssekvens.
5. Isoleret nukleinsyre ifølge krav 2, 3 eller 4, hvor cDNA'et er et influenzavirus-cDNA valgt fra gruppen bestående af: polymerase-basisprotein 2 (PB2)-cDNA, polymerase- basisprotein 1 (PBl)-cDNA, surt polymeraseprotein (PA, polymerase acidic protein)-cDNA, hæmagglutinin (HA)-cDNA, nukleoprotein (NP)-cDNA, neuraminidase (NA)-cDNA, matrixprotein 1 (Ml)-cDNA, matrixprotein 2 (M2)-cDNA, ikke- strukturprotein 1 (NSI, non-structural protein 1)- og ikke-strukturprotein 2 (NS2, non-structural protein 2)-cDNA.
6. Ekspressionsvektor, som omfatter en nukleinsyre ifølge et hvilket som helst af kravene 1-5.
7. Fremgangsmåde til frembringelse af et rekombinant influenzavirus, hvilken fremgangsmåde omfatter dyrkning af en hundecelle omfattende en ekspressionsvektor ifølge krav 6 og en eller flere ekspressionsvektorer, som udtrykker et mRNA, hvilket mRNA koder for et eller flere influenzapolypeptider valgt fra gruppen bestående af: polymerase- basisprotein 2 (PB2), polymerase-basisprotein 1 (PB1), surt polymeraseprotein (PA), hæmagglutinin (HA), nukleoprotein (NP), neuraminidase (NA), matrixprotein 1 (Ml), matrixprotein 2 (M2), ikke-strukturprotein 1 (NSI) og ikke-strukturprotein 2 (NS2), hvor mindst otte ekspressionsvektorer, som hver inkorporerer et influenzagenomsegment, hvilke influenzagenomsegmenter er forskellige, anvendes til at indføre et komplet influenzagenom i hundecellen; og isolering af det rekombinante influenzavirus.
8. Celle, som omfatter en ekspressionsvektor ifølge krav 6.
9. Fremgangsmåde til frembringelse af et genomisk influenza-RNA, hvilken fremgangsmåde omfatter indføring af ekspressionsvektoren ifølge krav 6 i hundeceller for derved at frembringe et genomisk influenza-RNA.
10. Fremgangsmåde til frembringelse af et rekombinant influenzavirus, hvilken fremgangsmåde omfatter i) indføring af ekspressionsvektorer i en population af hundeceller a) ekspression i cellerne af genomiske vRNA-segmenter for at tilvejebringe de komplette genomiske vRNA-segmenter for virusset, hvor en eller flere af ekspressionsvektorerne omfatter en nukleinsyresekvens for en hunde-RNA-polymerase I-promotor ifølge krav 1, og b) også ekspression i cellerne af mRNA, der koder for et eller flere influenzapolypeptider valgt fra gruppen bestående af: polymerase-basisprotein 2 (PB2), polymerase- basisprotein 1 (PB1), surt polymeraseprotein (PA), hæmagglutinin (HA), nukleoprotein (NP), neuraminidase (NA), matrixprotein 1 (Ml), matrixprotein 2 (M2), ikke- strukturprotein 1 (NSI) og ikke-strukturprotein 2 (NS2); og ii) dyrkning af cellerne, hvorved der frembringes influenzaviruspartikler.
11. Fremgangsmåde ifølge krav 9 eller 10, hvor hundecellerne er nyreceller.
12. Fremgangsmåde krav 10 eller 11, hvor det rekombinante influenzavirus er et reassortant virus.
13. Fremgangsmåde ifølge et hvilket som helst af kravene 10- 12, hvor frembragte influenzapartikler er infektiøse.
14. Fremgangsmåde ifølge et hvilket som helst af kravene 10- 13, hvor mRNA'et koder for hæmagglutininet (HA) og neuraminidasen (NA) fra en patogen influenzastamme.
15. Fremgangsmåde ifølge et hvilket som helst af kravene 10- 14, hvor mRNA'et koder for polymerase-basisprotein 2 (PB2), polymerase-basisprotein 1 (PB1), surt polymeraseprotein (PA), hæmagglutinin (HA), nukleoprotein (NP), neuraminidase (NA), matrixprotein 1 (Ml), matrixprotein 2 (M2), ikke- strukturprotein 1 (NSI) og ikke-strukturprotein 2 (NS2) fra en svækket influenzastamme.
16. Fremgangsmåde ifølge et hvilket som helst af kravene 10- 15, hvor det rekombinante virus er valgt fra gruppen bestående af: et kuldetilpasset influenzavirus, et svækket influenzavirus, et temperaturfølsomt influenzavirus og et svækket, temperaturfølsomt, kuldetilpasset influenzavirus.
17. Fremgangsmåde ifølge krav 16, hvor den svækkede influenzastamme er valgt fra gruppen bestående af A/Ann Arbor/6/60, B/Ann Arbor/1/66, B/Leningrad/14/17/55, B14/5/1, B/USSR/60/69, B/Leningrad/179/86, B/Leningrad/14/55, B/England/2608/76 og A/Puerto Rico/8/34.
18. Ekspressionsvektor pAD4000 ifølge SEQ ID NO: 29.
DK07760860.2T 2006-04-19 2007-04-18 Fremgangsmåder og sammensætninger til ekspression af viralt negativ-sense-rna i hundeceller DK2016194T3 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US79352206P 2006-04-19 2006-04-19
US79352506P 2006-04-19 2006-04-19
PCT/US2006/023867 WO2007002008A2 (en) 2005-06-21 2006-06-20 Methods and compositions for expressing negative-sense viral rna in canine cells
US11/455,734 US20060286591A1 (en) 2005-06-21 2006-06-20 Methods and compositions for expressing negative-sense viral RNA in canine cells
US11/501,067 US7790434B2 (en) 2005-06-21 2006-08-09 Methods and compositions for expressing negative-sense viral RNA in canine cells
PCT/US2007/066895 WO2007124327A2 (en) 2006-04-19 2007-04-18 Methods and compositions for expressing negative-sense viral rna in canine cells

Publications (1)

Publication Number Publication Date
DK2016194T3 true DK2016194T3 (da) 2015-06-15

Family

ID=38625719

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07760860.2T DK2016194T3 (da) 2006-04-19 2007-04-18 Fremgangsmåder og sammensætninger til ekspression af viralt negativ-sense-rna i hundeceller

Country Status (13)

Country Link
EP (2) EP2016194B1 (da)
JP (1) JP5491173B2 (da)
KR (1) KR101436176B1 (da)
CN (1) CN101528941B (da)
AU (1) AU2007240448B8 (da)
BR (1) BRPI0710626A2 (da)
CA (1) CA2646526C (da)
DK (1) DK2016194T3 (da)
ES (1) ES2539514T3 (da)
MX (1) MX2008013388A (da)
PT (1) PT2016194E (da)
RU (1) RU2457250C2 (da)
WO (1) WO2007124327A2 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
EP1917352A4 (en) * 2005-06-21 2009-03-25 Medimmune Vaccines Inc METHODS AND COMPOSITIONS FOR EXPRESSING HETEROLOGOUS PROTEASE
US7790434B2 (en) 2005-06-21 2010-09-07 Medimmune, Llc Methods and compositions for expressing negative-sense viral RNA in canine cells
JP5518041B2 (ja) 2008-03-18 2014-06-11 ノバルティス アーゲー インフルエンザウイルスワクチン抗原の調製における改良
US8785173B2 (en) 2008-09-24 2014-07-22 Medimmune, Llc Methods for purification of viruses
EA021009B1 (ru) 2009-05-21 2015-03-31 Новартис Аг ОБРАТНАЯ ГЕНЕТИКА С ИСПОЛЬЗОВАНИЕМ НЕЭНДОГЕННЫХ ПРОМОТОРОВ pol I
CN104862335A (zh) 2009-07-31 2015-08-26 诺华股份有限公司 反向遗传系统
CN103608453B (zh) 2012-03-02 2018-07-24 思齐乐 流感病毒重配
KR20150110494A (ko) 2012-12-03 2015-10-02 노파르티스 아게 재배열 인플루엔자 a 바이러스
SG11201507454XA (en) 2013-03-13 2015-10-29 Novartis Ag Influenza b virus reassortment
DE202013005100U1 (de) 2013-06-05 2013-08-26 Novartis Ag Influenza Virus Reassortierung
DE202013005130U1 (de) 2013-06-05 2013-09-10 Novartis Ag Influenza Virus Reassortierung
CN105722976A (zh) 2013-06-06 2016-06-29 诺华股份有限公司 流感病毒重配
US12178869B2 (en) 2017-12-22 2024-12-31 Codagenix Inc. Recombinant virus with codon-pair deoptimized region and uses thereof for the treatment of cancer
WO2019172982A1 (en) 2018-03-08 2019-09-12 Codagenix Inc. Attenuated flaviviruses
BR102020010208A2 (pt) 2020-05-21 2022-04-12 Fundação Oswaldo Cruz Construção de ácido nucleico, virus influenza recombinante, método para preparar um virus influenza recombinante, composição, e, uso.

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5840520A (en) 1989-08-28 1998-11-24 Aviron Recombinant negative strand RNA virus expression systems
US20060019350A1 (en) 1989-08-28 2006-01-26 Peter Palese Recombinant negative strand RNA virus expression system and vacccines
US6001634A (en) 1989-08-28 1999-12-14 Palese; Peter Recombinant negative strand RNA viruses
US5854037A (en) 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US5786199A (en) 1989-08-28 1998-07-28 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US6887699B1 (en) 1990-05-22 2005-05-03 Medimmune Vaccines, Inc. Recombinant negative strand RNA virus expression systems and vaccines
ATE257175T1 (de) 1994-07-18 2004-01-15 Conzelmann Karl Klaus Prof Dr Rekombinantes infektiöses nicht-in-segmente- geteiltes, negativ-strange-rns-virus
US5824536A (en) 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
US5789229A (en) 1994-09-30 1998-08-04 Uab Research Foundation Stranded RNA virus particles
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
US5690937A (en) 1995-06-05 1997-11-25 Aviron Temperature sensitive clustered changed-to-alanine mutants of influenza virus PB2 gene
ATE181112T1 (de) 1995-08-09 1999-06-15 Schweiz Serum & Impfinst Dem genom von minussträngigen rna-viren entsprechende cdna und verfahren zur herstellung von infektiösen minussträngigen rna-viren
AUPN475295A0 (en) 1995-08-11 1995-09-07 Liu, Richard A toilet bowl
US6264957B1 (en) 1995-09-27 2001-07-24 The United States Of America As Represented By The Department Of Health And Human Services Product of infectious respiratory syncytial virus from cloned nucleotide sequences
EP0780478A1 (en) 1995-12-21 1997-06-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for the indirect genotypic diagnosis of cadasil
IL118787A (en) 1996-07-04 2000-02-17 Israel State Method for applying plastic soil mulch
CA2265554A1 (en) 1996-09-27 1998-04-02 American Cyanamid Company 3' genomic promoter region and polymerase gene mutations responsible for attenuation in viruses of the order designated mononegavirales
BR9809456B1 (pt) 1997-05-23 2011-06-28 molécula isolada de polinucleotìdeo, composição de célula ou isenta de célula, partìcula de piv infeciosa, atenuada e imunogênica, e, composição imunogênica.
DE69837764T2 (de) 1997-07-11 2008-01-31 Yale University, New Haven Rhabdovirus mit gentechnisch veränderter hülle
KR20010030630A (ko) 1997-09-19 2001-04-16 윌리암 에이취 캘넌, 에곤 이 버그 약독화 호흡 신시티아 바이러스
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US8715940B2 (en) 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
ES2278621T5 (es) * 1999-07-14 2011-02-02 Mount Sinai School Of Medicine Of New York University Reconstrucción in vitro de virus arn segmentados de polaridad negativa.
ES2319864T3 (es) 2000-04-28 2009-05-14 St. Jude Children's Research Hospital Sistema de transfeccion de adn para la generacion de virus infecciosos de arn de cadena negativa.
KR101113432B1 (ko) 2002-02-13 2012-02-29 위스콘신 얼럼나이 리서어치 화운데이션 인플루엔자 바이러스 벡터의 패키징을 위한 신호
JP2005518209A (ja) 2002-02-21 2005-06-23 マウント シナイ スクール オブ メディシン 組換えマイナス鎖ウイルスｒｎａ発現系およびワクチン
DK1499348T3 (da) * 2002-04-26 2015-01-05 Medimmune Llc Fremgangsmåde til fremstilling af infektiøse influenza b-vira i cellekultur
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
EP2481819A1 (en) 2003-02-25 2012-08-01 MedImmune Vaccines, Inc. Cross flow filtration in the production of stabilized influenza vaccine compositions
CA2421086A1 (fr) * 2003-02-28 2004-08-28 Institut Pasteur Promoteur de l'arn polymerase i de poulet et son utilisation
CA2525953C (en) * 2003-05-28 2023-10-10 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines and gene therapy
WO2005028658A2 (en) 2003-05-28 2005-03-31 Wisconsin Alumni Research Foundation Recombinant influenza vectors with a polii promoter and ribozymes
CA2551489C (en) 2003-12-23 2013-09-03 Gregory Duke Multi plasmid system for the production of influenza virus
US7809118B2 (en) 2004-07-29 2010-10-05 Aspect Software, Inc. System and method for voice and data convergence
EP1917352A4 (en) * 2005-06-21 2009-03-25 Medimmune Vaccines Inc METHODS AND COMPOSITIONS FOR EXPRESSING HETEROLOGOUS PROTEASE

Also Published As

Publication number Publication date
EP2016194B1 (en) 2015-04-08
AU2007240448B8 (en) 2014-03-06
RU2457250C2 (ru) 2012-07-27
MX2008013388A (es) 2009-03-02
WO2007124327A2 (en) 2007-11-01
KR101436176B1 (ko) 2014-09-02
HK1136849A1 (en) 2010-07-09
EP2016194A4 (en) 2009-07-08
KR20090032030A (ko) 2009-03-31
AU2007240448A8 (en) 2014-03-06
ES2539514T3 (es) 2015-07-01
CN101528941A (zh) 2009-09-09
WO2007124327A3 (en) 2008-12-18
PT2016194E (pt) 2015-07-20
JP5491173B2 (ja) 2014-05-14
RU2008145226A (ru) 2010-05-27
CA2646526A1 (en) 2007-11-01
CA2646526C (en) 2016-01-12
BRPI0710626A2 (pt) 2011-08-16
EP2016194A2 (en) 2009-01-21
AU2007240448B2 (en) 2013-01-17
EP2431478A1 (en) 2012-03-21
CN101528941B (zh) 2014-03-12
JP2009534039A (ja) 2009-09-24
AU2007240448A1 (en) 2007-11-01

Similar Documents

Publication Publication Date Title
US8278433B2 (en) Methods and compositions for expressing negative-sense viral RNA in canine cells
DK2016194T3 (da) Fremgangsmåder og sammensætninger til ekspression af viralt negativ-sense-rna i hundeceller
JP5303603B2 (ja) インフルエンザウイルスの生産用多重プラスミドシステム
JP5264955B2 (ja) インフルエンザウイルス作製のための多重プラスミド系
US8097459B2 (en) Methods and compositions for increasing replication capacity of an influenza virus
US7790434B2 (en) Methods and compositions for expressing negative-sense viral RNA in canine cells
AU2013204811B2 (en) Methods and compositions for expressing negative-sense viral rna in canine cells
CN101243189A (zh) 用于在犬细胞内表达反义病毒rna的方法和组合物
HK1169448A (en) Methods and compositions for expressing negative-sense viral rna in canine cells
MX2008000245A (en) Methods and compositionsfor expressing negative-sense viral rna in canine cells